A common drug used to lower cholesterol has been shown to slow diabetic retinopathy progression according to findings presented at this year’s American Diabetes Association Scientific Sessions. Fenofibrate was shown to reduce disease progression by 27%. This marks the first large-scale trial designed to investigate the effect of the drug on eye outcomes for people with early diabetic retinopathy. Read about it in Modern Retina: https://lnkd.in/eVVUYwUZ #DiabeticRetinopathy #RetinopathyTreatments #VisionHealth
identifeye HEALTH
Medical Equipment Manufacturing
Guilford, CT 3,626 followers
We’re using innovative ML techniques to democratize access to the abundance of health insights available in the eye
About us
The eye is the window into the body. Identifeye Health is creating a non-invasive test that detects health conditions through the eyes. Identifeye Health is part of the 4Catalyzer accelerator, with over $700 Million in funding, 300 scientists and engineers. Our offices are in Guilford CT, New York City, and Palo Alto. 4Catalyzer is founded by Jonathan Rothberg, the inventor of “Next-Gen” DNA sequencing and ultrasound-on-a-chip (Butterfly Network).
- Website
-
https://www.identifeye.health/
External link for identifeye HEALTH
- Industry
- Medical Equipment Manufacturing
- Company size
- 11-50 employees
- Headquarters
- Guilford, CT
- Type
- Privately Held
- Founded
- 2018
Locations
-
Primary
530 Old Whitfield Rd
Guilford, CT 06437, US
-
735 Shasta Street
Redwood City, CA 94063, US
Employees at identifeye HEALTH
-
Maya Venkatraman
-
Jonathan Rothberg
#ThanksObama - email joinus@4Catalyzer.com to help save the life of someone you love. Follow me on Twitter @JMRothberg
-
David Rosenthal M.D.
Healthcare advisor, investor, and entrepreneur. Physician & Faculty @Yale | Venture Partner @ Alleycorp | Former Chief Medical Officer @Tesseract…
-
Noah Wilson
Staff Embedded Software Engineer at Identifeye Health
Updates
-
Diabetic macular edema (DME) is a complication of diabetic retinopathy that’s caused by fluid buildup in the retina. While DME can occur at any stage of diabetic retinopathy, there’s an increased risk as the disease progresses. Healthline Media answers frequent questions here: https://lnkd.in/eA-uEgGd #DiabeticRetinopathy #MacularEdema #VisionHealth
-
Researchers at the University of Oklahoma and Memorial Sloan Kettering Cancer Center have made advancements for a potential new treatment of diabetic retinopathy, a major complication of diabetes that can lead to blindness. The new approach, detailed in a paper published in Cell Metabolism by Julia Busik and Richard Kolesnick, focuses on anti-ceramide immunotherapy to tackle the disease at its root by targeting harmful lipid build-ups in the retina. This innovative treatment addresses the core cause but also offers a less invasive alternative to current methods that involve eye injections or laser treatments. The therapy, shown to be effective in animal and cell studies, promises to intervene much earlier in the disease's progression, potentially preventing severe damage and preserving vision for diabetic patients. Read about the findings in Medical Xpress: https://lnkd.in/ekg4rsdP #DiabeticRetinopathy #RetinopathyTreatments #VisionHealth
Potential new treatment option for diabetic retinopathy could address the problem much earlier
medicalxpress.com
-
Research from the University of Oklahoma presents a new potential therapeutic for diabetic retinopathy. Julia Busik and Richard Kolesnick recently published a paper in Cell Metabolism detailing how anti-ceramide immunotherapy can address the root cause of the disease. This treatment could be administered systemically, bypassing treatments like eye injections altogether. This research is still in its early stages, but the potential for improved outcomes and earlier intervention for diabetic retinopathy patients is significant. Full story and study can be found in Medical Xpress: https://lnkd.in/gkfFVrxT #DiabeticRetinopathy #RetinopathyTreatments
Potential new treatment option for diabetic retinopathy could address the problem much earlier
medicalxpress.com
-
People with diabetic retinopathy have several treatment options to help slow disease progression. In the early stages of the disease, doctors may forgo treatment and instead opt for more frequent eye exams while the vision is still good. If vision begins to decline, some treatment options include injections, laser treatment, or eye surgery. Learn more about treatment options from the Cleveland Clinic here: https://lnkd.in/exXUetbW #DiabeticRetinopathy #RetinopathyTreatments
Diabetes-Related Retinopathy: Symptoms, Treatment & Causes
my.clevelandclinic.org
-
There’s an increase in diabetic retinopathy prevalence among younger adults and minority groups, according to a study that investigated trends of the disease. A new commentary article in JAMA Ophthalmology examines the data and provides insights into the likely reasons behind the rise in prevalence. Factors include increased awareness of diabetic retinopathy screening and a greater focus on the disease due to the availability of new and effective treatments. Learn more here: https://lnkd.in/es94nc8n #DiabeticRetinopathy #diabetes #eyehealth
Prevalence of Diabetic Retinopathy in Health Care Settings
jamanetwork.com
-
While diabetic retinopathy can be difficult to prevent, there are steps people with diabetes can take to lower the risk of disease development and progression. This includes receiving annual eye exams, managing diabetes, and monitoring for any vision changes. Johns Hopkins Medicine has more details on disease management: https://lnkd.in/gBsmb_Cy
-
Diabetic Macular Edema is a severe form of diabetic retinopathy. Current treatments are effective for most people, but not all. A new episode of Drug Discovery News podcast, DDN Dialogues, covers a potential new way to treat diabetic vision loss by rejuvenating the retina by targeting senescent cells. Learn more about how this is done and what the research says here: https://lnkd.in/e8XQz7UM #DiabeticRetinopathy #DiabeticVision
Rejuvenating the retina to save vision
drugdiscoverynews.com
-
New treatments for diabetic retinopathy are constantly evolving, with significant potential impacts on people affected by the disease. In this podcast episode of DDN Dialogues, host Stephanie DeMarco, and guest Mike Sapieha delve into the intriguing concept of senescent cells—cells that are in a state between life and death and contribute to aging and age-related diseases. Sapieha discusses his recent study, which developed a senolytic drug targeting these senescent cells in the eye. The study shows promising results for treating diabetic macular edema, offering the potential for longer-lasting benefits compared to current treatments, marking a significant advancement in managing eye conditions linked to cellular senescence. Drug Discovery News has insights about how it works: https://lnkd.in/gCMZzs4d What are your thoughts on this new approach? #DiabeticRetinpathy
Rejuvenating the retina to save vision
drugdiscoverynews.com
-
Who’s at risk for developing diabetic retinopathy? According to the National Eye Institute (NEI), anyone with diabetes can get diabetic retinopathy. This includes people with Type 1, 2 and gestational diabetes. The longer you have diabetes, the greater the chance of developing retinopathy. However, good news is you can significantly reduce your risk by effectively managing blood sugar levels. The NEI has more details and resources here: https://lnkd.in/ex7NiRZT. #EyeonDiabetes #diabetesawareness #eyehealth